Logo

AstraZeneca Advances its AZD7442 in Two P-III Clinical Studies for COVID-19

Share this

AstraZeneca Advances its AZD7442 in Two P-III Clinical Studies for COVID-19

Shots:

  • The two studies of AZD7442 will enroll ~6-000 adults for the prevention of COVID-19 in and outside the US- expected to begin in next wk. with additional trials enrolling ~4-000 adults for the treatment of SARS-CoV-2 infections.
  • The first study will evaluate the safety and efficacy of AZD7442 to prevent infection for up to 12mos. in ~5-000 participants while the second trial will assess post-exposure prophylaxis and pre-emptive treatment in ~1-100 participants
  • AstraZeneca has received ~$486M from US Govt. and plans to supply ~100-000 doses and can acquire other 1M doses. AZD7442 is a combination of 2 LAABs derived from convalescent patients after SARS-CoV-2 infection

     ­ Ref: AstraZeneca | Image: The Scientist Magazine
Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions